Motley Rice Actos® lawyers are reviewing potential Actos® lawsuits involving patients who took the diabetes drugs Actos® or Duetact® for more than one year and developed bladder cancer.
Actos®, generically known as pioglitazone, is an oral diabetes drug prescribed to help control Type 2 diabetes in patients whose conditions are not adequately controlled by diet and exercise alone. The drug belongs to a class of drugs called thiazolidinedione drugs and is intended to lower blood glucose levels and increase the body's sensitivity to insulin.
Actos®, or pioglitazone, is found in the diabetes drug Duetact®. Duetact® contains a combination of pioglitazone and glimepiride, both oral diabetes medicines that help control blood sugar levels.
Contact an Actos® Lawyer
If you or someone you know took Actos® or Duetact® and developed bladder cancer and have questions about a possible Actos® Lawsuit, contact Actos® lawyer Kimberly Barone Baden by email or call 1.800.768.4026 .
Actos® Side Effects
The Food and Drug Administration (FDA) has warned that there may be a link between long-term use of Actos® or Duetact® and bladder cancer.
Actos® and Duetact® are manufactured by Takeda Pharmaceutical Company Limited and co-marketed in the United States by Eli Lilly and Company, the world's 10th largest pharmaceutical company.
On April 7, 2014, a federal court jury ordered that $9 billion in punitive damages be paid from Takeda and Lilly. The jury found that the companies hid the cancer risks related to Actos®.
In June 2011, the FDA issued an Actos® warning to doctors and patients that "use of the diabetes pioglitazone for more than one year may be associated with an increased risk of bladder cancer." The FDA also stated that the Actos® label and patient Medication Guide will be changed to reflect the potential risk of bladder cancer. This announcement was based on the FDA's review of an ongoing, ten-year study revealing a disproportionate risk of developing bladder cancer with pioglitazone use. Both Actos® and Duetact® were cited in this announcement. The study reports that there may be a 40 percent increased risk of bladder cancer among those take Actos® for more than one year.
Some countries have taken a more aggressive approach to limiting the sale and prescription of Actos®. Following the release of a French study showing a possible increased risk of bladder cancer with Actos® use, both France and Germany suspended sales and prescriptions of the drug.
According to the FDA website, the FDA will continue to monitor data from the ten-year study and will conduct a comprehensive review of the results from the French study. The Agency will also provide updates to the public when more information becomes available.
Learn more about prescription drug lawsuits and your legal rights.